MTOR and central nervous system cancer: Because cediranib targets both PDGF and VEGF signaling, inhibition of which can have downstream inhibitory effects on the PI3K/Akt/mTOR pathway [3], [4], [5], [20], [31], we assessed whether cediranib treatment affected Akt kinase activation in 4C8 glioma cells.